Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Research

Association between metabolic syndrome and early-stage colorectal cancer

Authors: Chenchen Zhang, Liting Zhang, Yan Tian, Bingxin Guan, Shuai Li

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Accumulating studies have suggested metabolic syndrome (MetS) contributed to colorectal cancer (CRC) development. However, advanced CRC might decrease the detection proportion of MetS due to chronic malnutrition, we included patients with early-stage CRC to examine the associations among MetS, onset age, and different tumorigenesis pathways of CRC.

Methods

We conducted a retrospective study that included 638 patients with early-stage CRC from January 2014 to December 2018. Patient information was collected from the medical record system and further refined during the follow-up. Stratified analyses of the associations between MetS and different stratification factors were determined by the Cochran‒Mantel‒Haenszel test.

Results

There were 16 (13.3%) and 111 (21.4%) cases suffering from MetS in the early-onset and late-onset CRC groups, respectively. MetS coexisted in early-stage CRC patients ≥ 50 years of age more frequently than patients < 50 years of age (OR 1.77; 95% CI 1.01 to 3.12), but not for women patients (OR 0.84; 95% CI 0.79 to 0.90). MetS patients were associated with a higher risk of advanced serrated lesions than that of conventional adenomas (OR 1.585; 95% CI 1.02 to 2.45), especially in patients ≥ 50 years (OR 1.78; 95% CI 1.11 to 2.85).

Conclusions

Metabolic dysregulation might partly contribute to the incidence of colorectal serrated lesions. Prevention of MetS should be highly appreciated in the early diagnosis and early treatment of the colorectal cancer system, especially in patients ≥ 50 years.
Appendix
Available only for authorised users
Literature
1.
Shaukat A, Kahi CJ, Burke CA, et al. ACG clinical guidelines: Colorectal Cancer Screening 2021. Am J Gastroenterol. 2021;116:458–79.CrossRefPubMed
2.
Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer the Lancet. 2019;394:1467–80.
3.
Sinicrope FA. Increasing incidence of early-onset Colorectal Cancer. N Engl J Med. 2022;386:1547–58.CrossRefPubMed
4.
Hofseth LJ, Hebert JR, Chanda A, et al. Early-onset Colorectal cancer: initial clues and current views. Nat Rev Gastroenterol Hepatol. 2020;17:352–64.CrossRefPubMed
5.
National Cancer Center CEGotDoCGftSED. Early treatment of Colorectal Cancer. [China guideline for the screening, early detection and early treatment of Colorectal cancer (2020, Beijing)]. Zhonghua Zhong Liu Za Zhi. 2021;43:16–38.
6.
7.
Shen X, Wang Y, Zhao R, et al. Metabolic syndrome and the risk of Colorectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis. 2021;36:2215–25.CrossRefPubMed
8.
Fahed G, Aoun L, Bou Zerdan M et al. Metabolic syndrome: updates on pathophysiology and management in 2021. Int J Mol Sci 2022;23.
9.
Mili N, Paschou SA, Goulis DG, et al. Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. Endocrine. 2021;74:478–97.CrossRefPubMed
10.
Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 Diabetes Mellitus in China (2020 edition). Chin J Diabetes. 2021;13:315–409.
11.
12.
Strauss M, Lavie CJ, Lippi G, et al. A systematic review of prevalence of metabolic syndrome in occupational groups - does occupation matter in the global epidemic of metabolic syndrome? Prog Cardiovasc Dis; 2022.
13.
Bishehsari F, Voigt RM, Keshavarzian A. Circadian rhythms and the gut microbiota: from the metabolic syndrome to cancer. Nat Rev Endocrinol. 2020;16:731–9.CrossRefPubMedPubMedCentral
14.
Kabat GC, Kim MY, Lee JS, et al. Metabolic obesity phenotypes and risk of Breast Cancer in Postmenopausal Women. Cancer Epidemiol Biomarkers Prev. 2017;26:1730–5.CrossRefPubMedPubMedCentral
15.
Battelli MG, Bortolotti M, Polito L, et al. Metabolic syndrome and cancer risk: the role of xanthine oxidoreductase. Redox Biol. 2019;21:101070.CrossRefPubMed
16.
Chen H, Zheng X, Zong X, et al. Metabolic syndrome, metabolic comorbid conditions and risk of early-onset Colorectal cancer. Gut. 2021;70:1147–54.CrossRefPubMed
17.
Wu H, Zhang J, Zhou B. Metabolic syndrome and colorectal adenoma risk: a systematic review and metaanalysis. Clin Res Hepatol Gastroenterol. 2021;45:101749.CrossRefPubMed
18.
Choi YJ, Lee DH, Han KD, et al. Abdominal obesity, glucose intolerance and decreased high-density lipoprotein cholesterol as components of the metabolic syndrome are associated with the development of Colorectal cancer. Eur J Epidemiol. 2018;33:1077–85.CrossRefPubMed
19.
Shin J, Kim ER, Jang HJ, et al. Long-term prognosis of curative endoscopic submucosal dissection for early Colorectal cancer according to submucosal invasion: a multicenter cohort study. BMC Gastroenterol. 2022;22:417.CrossRefPubMedPubMedCentral
20.
Bronswijk M, Rasschaert G, Hayashi Y, et al. Colorectal endoscopic submucosal dissection: a review on patient selection and indications. Acta Gastroenterol Belg. 2023;86:36–46.CrossRefPubMed
21.
Chen B, Scurrah CR, McKinley ET, et al. Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. Cell. 2021;184:6262–80. e26.CrossRefPubMedPubMedCentral
22.
Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182–8.CrossRefPubMed
23.
Tian Y, Xin Y, Li S. Risk stratification based on synchronous neoplasia and clinical physicochemical characteristics predicts a higher incidence of Metachronous Advanced Neoplasia in patients undergoing colorectal resection for Colorectal Cancer. Cancer Manag Res. 2020;12:11295–307.CrossRefPubMedPubMedCentral
24.
Jimba T, Kaneko H, Yano Y, et al. Relation of the metabolic syndrome to Incident Colorectal Cancer in Young adults aged 20 to 49 years. Am J Cardiol. 2021;158:132–8.CrossRefPubMed
25.
Kasprzak A. Insulin-like growth factor 1 (IGF-1) signaling in glucose metabolism in Colorectal Cancer. Int J Mol Sci 2021;22.
26.
Lu B, Qian JM, Li JN. The metabolic syndrome and its components as prognostic factors in Colorectal cancer: a Meta-analysis and systematic review. J Gastroenterol Hepatol 2022.
27.
Bae CY, Piao M, Kim M, et al. Biological age and lifestyle in the diagnosis of metabolic syndrome: the NHIS health screening data, 2014–2015. Sci Rep. 2021;11:444.CrossRefPubMedPubMedCentral
28.
Lemieux I, Despres JP. Metabolic syndrome: past, Present and Future. Nutrients 2020;12.
29.
Bird SR, Hawley JA. Update on the effects of physical activity on insulin sensitivity in humans. BMJ Open Sport Exerc Med. 2016;2:e000143.CrossRefPubMed
30.
Martin-Pelaez S, Fito M, Castaner O. Mediterranean Diet effects on type 2 Diabetes Prevention, Disease Progression, and related mechanisms. A Review. Nutrients 2020;12.
31.
Matheus VA, Monteiro L, Oliveira RB, et al. Butyrate reduces high-fat diet-induced metabolic alterations, hepatic steatosis and pancreatic beta cell and intestinal barrier dysfunctions in prediabetic mice. Exp Biol Med (Maywood). 2017;242:1214–26.CrossRefPubMed
32.
Jia W, Bai T, Zeng J, et al. Combined Administration of Metformin and Atorvastatin attenuates Diabetic Cardiomyopathy by inhibiting inflammation, apoptosis, and oxidative stress in type 2 Diabetic mice. Front Cell Dev Biol. 2021;9:634900.CrossRefPubMedPubMedCentral
33.
Burnett-Hartman AN, Lee JK, Demb J, et al. An update on the epidemiology, molecular characterization, diagnosis, and screening strategies for early-onset Colorectal Cancer. Gastroenterology. 2021;160:1041–9.CrossRefPubMed
34.
He Q, Zhang H, Yao S et al. A study on relationship between metabolic syndrome and Colorectal cancer. J BUON 2018;Sep-Oct;23(5):1362–8.
35.
Kordahi MC, Stanaway IB, Avril M, et al. Genomic and functional characterization of a mucosal symbiont involved in early-stage Colorectal cancer. Cell Host Microbe. 2021;29:1589–98. e6.CrossRefPubMedPubMedCentral
36.
Tong K, Pellon-Cardenas O, Sirihorachai VR, et al. Degree of tissue differentiation dictates susceptibility to BRAF-Driven Colorectal Cancer. Cell Rep. 2017;21:3833–45.CrossRefPubMedPubMedCentral
37.
Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541–6.CrossRefPubMed
38.
Hills RD Jr., Pontefract BA, Mishcon HR et al. Gut microbiome: profound implications for Diet and Disease. Nutrients 2019;11.
39.
Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and Diabetes in mice. Diabetes. 2008;57:1470–81.CrossRefPubMed
40.
41.
Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027–31.CrossRefPubMed
42.
Verdam FJ, Fuentes S, de Jonge C, et al. Human intestinal microbiota composition is associated with local and systemic inflammation in obesity. Obes (Silver Spring). 2013;21:E607–615.CrossRef
43.
Kootte RS, Levin E, Salojarvi J et al. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metab 2017;26:611–619 e6.
Metadata
Title
Association between metabolic syndrome and early-stage colorectal cancer
Authors
Chenchen Zhang
Liting Zhang
Yan Tian
Bingxin Guan
Shuai Li
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11537-3

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: a comparison of two sequencing methods and gene sets using FFPE specimens

Research

Clinicopathological features and prognosis of patients with HER2-low breast cancer

Research

Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin

Research

Development and validation of a selenium metabolism regulators associated prognostic model for hepatocellular carcinoma

Research

Circular RNA ZNF800 (hsa_circ_0082096) regulates cancer stem cell properties and tumor growth in colorectal cancer

Research article

Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits